Preliminary revenue for the first quarter was below the company’s expectations due to an increasing number of customers delaying instrument purchases and softness in consumable shipments. All regions underperformed, with 13 Revio systems falling out of the forecast in the last couple of weeks in the first quarter, which the company believes primarily resulted from elongated customer purchasing cycles. The median sales cycle for Revio instrument purchases increased more than expected in the first quarter of 2024. PacBio believes that these instruments continue to be strong sales opportunities that are likely to close in 2024.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PACB:
- Cathie Wood’s ARK Investment bought 349K shares of PacBio today
- PacBio price target lowered to $3 from $8 at Barclays
- Cathie Wood’s ARK Investment bought 190K shares of PacBio today
- Cathie Wood’s ARK Investment bought 273K shares of PacBio today
- PacBio’s Revio HiFi sequencing system selected by University of Tartu